罗格列酮抑制肝星状细胞活化的作用机制研究  

Mechanism of rosiglitazone suppressing the activation of hepatic stellate cells

作　　者：郭晏同[1] 赵景明[1] 王欣[1] 周迈[2] 焦岗军[2] 钟朝辉[3] 李涛[3] 冷希圣[3] 

机构地区：[1]北京积水潭医院,北京100035 [2]民航总医院 [3]北京大学人民医院

出　　处：《山东医药》2008年第19期6-8,共3页Shandong Medical Journal

基　　金：国家自然科学基金资助项目(30371387)

摘　　要：目的探讨罗格列酮对大鼠肝星状细胞生物学特性的影响是否是通过PPARγ起作用。方法设立10μmol/L罗格列酮组、GW9662加10μmol/L罗格列酮组、对照组、GW9662组。采用RT-PCR方法检测PPARγ及Ⅰ型前胶原mRNA表达;用Western blot法检测PPARγ及Ⅰ型胶原蛋白表达;电泳迁移分析法(EMSA)检测PPARγ蛋白的结合活性;用免疫细胞化学方法测定α-平滑肌肌动蛋白(α-SMA)表达的变化。结果10μmol/L罗格列酮组PPARγmRNA及蛋白表达显著高于其他各组(P<0.01),Ⅰ型前胶原mRNA及蛋白表达明显低于其他各组(P<0.01);10μmol/L罗格列酮组PPARγ蛋白结合活性最强,α-SMA表达明显低于其他组(P<0.05)。结论罗格列酮对大鼠肝星状细胞的影响是通过PPARγ起作用的。Objective To identify whether the effect of rosiglitazone on the biological characters of hepatic stellate cells （HSCs） being carried out through peroxisome proliferator-activated receptor gamma （PPART）. Methods The activated HSCs were divided into four groups： 10 umol/L rosiglitazone group, GW9662 with 10 umol/L rosightazone group, the control group and GW9662 group. The expression of PPARγ, and type I pro-collagen at mRNA level was detected by reverse transcription polymerase chain reaction （RT-PCR）. The expressions of PPARγ, and type I collagen were measured by western blot. Protein binding activity of PPARγ, was evaluated by electrophoretic mobility shift assay （EMSA）. The variation of expression of a-SMA was measured by immunocytochemistry. Results Compared with other groups, the expression of PPARγ, of mRNA and protein level in 10 umol/L rosiglitazone group was significantly increased （ P 〈0.01 ）, while the expression of type I pro-collagen of mRNA and protein level was significantly reduced （P 〈 0.01 ）. Protein binding activity of PPAR3, was strongest in 10umol/L rosiglitazone group. The expression of α-SMA in 10 panol/L rosightazone group was significantly lower than those in other groups. Conclusion The effect of rosightazone on hepatic stellate cells of rats may be carried out through PPARγ

关 键 词：肝星状细胞 PPARΓ 罗格列酮 肝纤维化 

分 类 号：R329.2[医药卫生—人体解剖和组织胚胎学] R392.12[医药卫生—基础医学]